Arcus Biosciences (RCUS) Tops Q4 EPS by 20c

Arcus Biosciences (NYSE: RCUS) reported Q4 EPS of ($1.03), $0.20 better than the analyst estimate of ($1.23). Revenue for the quarter came in at $36 million versus the consensus estimate of $29.33 million.

For earnings history and earnings-related data on Arcus Biosciences (RCUS) click here.

You May Also Be Interested In

• Gulfport Energy and Mobility Global to join S&P SmallCap 600
• FDA approves AbbVie's Skyrizi for children with psoriatic disease
• Uranium Royalty Corp. sets shareholder vote on $1.14B Sweetwater deal